AG
NKTR icon

Advisor Group’s Nektar Therapeutics NKTR Stock Holding History

Advisor Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$232K Buy
715
+8
+1% +$2.32K ﹤0.01% 2278
2019
Q3 		$193K Sell
707
-80
-10% -$29.3K ﹤0.01% 2351
2019
Q2 		$420K Buy
787
+246
+45% +$123K ﹤0.01% 1741
2019
Q1 		$274K Buy
541
+98
+22% +$58.1K ﹤0.01% 2023
2018
Q4 		$218K Buy
443
+78
+21% +$47.1K ﹤0.01% 2027
2018
Q3 		$334K Buy
365
+263
+258% +$224K ﹤0.01% 1782
2018
Q2 		$75K Buy
102
+12
+13% +$13.8K ﹤0.01% 2769
2018
Q1 		$144K Sell
90
-19
-17% -$24.5K ﹤0.01% 2248
2017
Q4 		$97K Buy
109
+5
+5% +$2.96K ﹤0.01% 2603
2017
Q3 		$38K Buy
104
+1
+1% +$313 ﹤0.01% 3136
2017
Q2 		$31K Buy
103
+16
+18% +$4.62K ﹤0.01% 3173
2017
Q1 		$31K Buy
87
+8
+10% +$1.8K ﹤0.01% 3056
2016
Q4 		$14K Sell
79
-24
-23% -$4.88K ﹤0.01% 3453
2016
Q3 		$27K Buy
103
+7
+7% +$1.8K ﹤0.01% 2963
2016
Q2 		$19K Buy
+96
New +$21.5K ﹤0.01% 3098

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Advisor Group's NKTR Position: Q4 2019 in Review

Advisor Group increased its Nektar Therapeutics (NKTR) stake by 1.1% in Q4 2019, buying an estimated $2.32K and bringing the position to 715 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

Advisor Group first reported a position in NKTR in Q2 2016 and has held it in 15 quarters since. The position peaked at $420K in Q2 2019. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Advisor Group held 715 shares of Nektar Therapeutics worth $232K as of Q4 2019.
  • Advisor Group bought 8 Nektar Therapeutics shares in Q4 2019, an estimated $2.32K.
  • Nektar Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2278 holding.
  • Advisor Group first reported a position in Nektar Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Nektar Therapeutics position peaked at $420K in Q2 2019.
  • 280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.